These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1159815)

  • 21. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
    [No Abstract]   [Full Text] [Related]  

  • 22. [Depression of the immune response to lymphoma allotransplant with the use of 5-(3,3-dimethyl-1-triazeno)-imidazol-4-carboxamide (DTIC)].
    Giampietri A; Puccetti P; Circolo A; Menconi E
    Boll Soc Ital Biol Sper; 1977 Jun; 53(11):922-6. PubMed ID: 597414
    [No Abstract]   [Full Text] [Related]  

  • 23. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
    Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity induced in vivo by DIC in relatively non-immunogenic leukemias.
    Nicolin A; Cavalli M; Missiroli A; Goldin A
    Eur J Cancer (1965); 1977 Mar; 13(3):235-9. PubMed ID: 862643
    [No Abstract]   [Full Text] [Related]  

  • 26. Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
    Marelli OE; Franco P; Labeta MO; Festenstein H
    J Immunogenet; 1989; 16(4-5):373-80. PubMed ID: 2639909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
    Nicolin A; Bini A; Franco P; Goldin A
    Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
    [No Abstract]   [Full Text] [Related]  

  • 28. The immunodepressive and hematotoxic activity of imidazole-4-carboxamide,5-(3,3-dimethyl-1-triazeno) in mice.
    Vecchi A; Fioretti MC; Mantovani A; Barzi A; Spreafico F
    Transplantation; 1976 Dec; 22(6):619-24. PubMed ID: 795112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs.
    Bonmassar E; Testorelli C; Franco P; Goldin A; Cudkowicz G
    Cancer Res; 1975 Aug; 35(8):1957-62. PubMed ID: 1149019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of modified tumor cells in syngenic hosts.
    Prager MD; Gordon WC; Baechtel FS
    Ann N Y Acad Sci; 1976; 276():61-74. PubMed ID: 1071980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies.
    Nardelli B; Puccetti P; Romani L; Sava G; Bonmassar E; Fioretti MC
    Cancer Immunol Immunother; 1984; 17(3):213-7. PubMed ID: 6566603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.
    Puccetti P; Fuschiotti P; Dominici P; Borri-Voltattorni C; Romani L; Fioretti MC
    Int J Cancer; 1987 Jun; 39(6):769-73. PubMed ID: 2438236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 36. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro.
    Fuji H; Mihich E; Pressman D
    J Immunol; 1977 Sep; 119(3):983-6. PubMed ID: 330761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo.
    Santoni A; Kinney Y; Goldin A
    J Natl Cancer Inst; 1978 Jan; 60(1):109-12. PubMed ID: 146746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC).
    Puccetti P; Giampietri A; Fioretti MC
    Experientia; 1978 Jun; 34(6):799-800. PubMed ID: 658308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H; Murakami M
    J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.